Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.
You may also be interested in...
Benicar Sales Aid Draws FDA Warning Letter
Agency objects to superiority and efficacy claims for the Forest/Sankyo angiotension II receptor blocker based on misleading comparisons and inadequate studies.
Benicar Sales Aid Draws FDA Warning Letter
Agency objects to superiority and efficacy claims for the Forest/Sankyo angiotension II receptor blocker based on misleading comparisons and inadequate studies.
Forest Credits Lexapro Growth To Less Detailing By Competitors
The antidepressant market has “normalized” following suicidality concerns, COO Goodman says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: